U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07884344) titled 'Window of Opportunity Study of Lixumistat in Patients With Newly Diagnosed Glioblastoma' on Aug. 31.
Brief Summary: The purpose of this study is to determine the effect of Lixumistat in patients with newly diagnosed Glioblastoma.
Study Start Date: Dec. 01
Study Type: INTERVENTIONAL
Condition:
Glioblastoma
Intervention:
DRUG: Lixumistat - Cohort 1
Participants will receive Lixumistat 400 mg administered orally once daily for up to four days prior to surgery. If the surgical procedure is delayed by up to two days, dosing may continue for a maximum total of six days.
DRUG: Lixumistat - Cohort 2
Participants will receive Lixumi...